To read the full story, subscribe or sign in.

Gene editing alleviates AD deficits in mouse models

March 14, 2019

No Comments

BioWorld Science Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for Nov. 15, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 15, 2024.

Gray and green glass dollar symbols with arrow pointing up

Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly

BioWorld

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....

Australia reimburses Vazkepa a decade after US approval

BioWorld

For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

GLP-1s push into MASH as semaglutide 2.4 mg hits endpoints

BioWorld

Positive findings from a phase III trial of semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) is moving Novo Nordisk A/S to expand the...

Upgrade your daily dose of biopharma and medtech news

Gene editing alleviates AD deficits in mouse models